Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Nitrate and ammonium fluxes to diatoms and dinoflagellates at a single cell level in mixed field communities in the sea.

Olofsson M, Robertson EK, Edler L, Arneborg L, Whitehouse MJ, Ploug H.

Sci Rep. 2019 Feb 5;9(1):1424. doi: 10.1038/s41598-018-38059-4.

2.

Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).

von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T.

Phytomedicine. 2019 Feb 15;54:140-148. doi: 10.1016/j.phymed.2018.09.178. Epub 2018 Sep 17.

PMID:
30668363
3.

Nitrogen uptake potential under different temperature-salinity conditions: Implications for nitrogen cycling under climate change scenarios.

Kumar S, Bhavya PS, Ramesh R, Gupta GVM, Chiriboga F, Singh A, Karunasagar I, Rai A, Rehnstam-Holm AS, Edler L, Godhe A.

Mar Environ Res. 2018 Oct;141:196-204. doi: 10.1016/j.marenvres.2018.09.001. Epub 2018 Sep 4.

PMID:
30213661
4.

A critical evaluation of health risk assessment of modified mycotoxins with a special focus on zearalenone.

Lorenz N, Dänicke S, Edler L, Gottschalk C, Lassek E, Marko D, Rychlik M, Mally A.

Mycotoxin Res. 2019 Feb;35(1):27-46. doi: 10.1007/s12550-018-0328-z. Epub 2018 Sep 13.

5.

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.

Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC.

Oncotarget. 2017 Jun 27;8(44):76029-76043. doi: 10.18632/oncotarget.18635. eCollection 2017 Sep 29.

6.

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).

von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Edler L, Munzinger J, Efferth T, Schneeweiss A, Strowitzki T.

Breast Cancer Res Treat. 2017 Jul;164(2):359-369. doi: 10.1007/s10549-017-4261-1. Epub 2017 Apr 24.

PMID:
28439738
7.

Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.

König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1321. No abstract available.

PMID:
27094900
8.

Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.

Habl G, Uhl M, Katayama S, Kessel KA, Hatiboglu G, Hadaschik B, Edler L, Tichy D, Ellerbrock M, Haberer T, Wolf MB, Schlemmer HP, Debus J, Herfarth K.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):435-43. doi: 10.1016/j.ijrobp.2016.02.025. Epub 2016 Feb 12.

PMID:
27084659
9.

Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.

König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S.

Cancer Chemother Pharmacol. 2016 Feb;77(2):413-27. doi: 10.1007/s00280-016-2960-7. Epub 2016 Jan 21. Erratum in: Cancer Chemother Pharmacol. 2016 Jun;77(6):1321.

PMID:
26793976
10.

Reproducible research in statistics: A review and guidelines for the Biometrical Journal.

Hofner B, Schmid M, Edler L.

Biom J. 2016 Mar;58(2):416-27. doi: 10.1002/bimj.201500156. Epub 2015 Dec 29.

PMID:
26711717
11.

Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.

Habl G, Katayama S, Uhl M, Kessel KA, Edler L, Debus J, Herfarth K, Sterzing F.

BMC Cancer. 2015 Nov 7;15:868. doi: 10.1186/s12885-015-1886-5.

12.

Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status.

Hildebrandt W, Sauer R, Bonaterra G, Dugi KA, Edler L, Kinscherf R.

Am J Clin Nutr. 2015 Nov;102(5):1014-24. doi: 10.3945/ajcn.114.101964. Epub 2015 Oct 7.

PMID:
26447155
13.

Unsustainable claims.

Lelgemann M, Wild C, Antes G, Edler L, Ernst E, Gärtner J, Schmacke N.

Dtsch Arztebl Int. 2015 Jan 5;112(1-2):10-1. doi: 10.3238/arztebl.2015.0010b. No abstract available.

14.

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H.

Eur J Cancer. 2015 Jan;51(1):27-36. doi: 10.1016/j.ejca.2014.10.010. Epub 2014 Nov 5.

PMID:
25459392
15.

Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.

Katayama S, Striecker T, Kessel K, Sterzing F, Habl G, Edler L, Debus J, Herfarth K.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):926-33. doi: 10.1016/j.ijrobp.2014.07.015. Epub 2014 Sep 9.

PMID:
25216858
16.

Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.

Uhl M, Edler L, Jensen AD, Habl G, Oelmann J, Röder F, Jäckel O, Debus J, Herfarth K.

Radiat Oncol. 2014 Apr 29;9:100. doi: 10.1186/1748-717X-9-100.

17.

Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.

Habl G, Hatiboglu G, Edler L, Uhl M, Krause S, Roethke M, Schlemmer HP, Hadaschik B, Debus J, Herfarth K.

BMC Cancer. 2014 Mar 19;14:202. doi: 10.1186/1471-2407-14-202.

18.

Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.

Katayama S, Habl G, Kessel K, Edler L, Debus J, Herfarth K, Sterzing F.

BMC Cancer. 2014 Jan 14;14:20. doi: 10.1186/1471-2407-14-20.

19.
20.

Disparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas.

Hoensch HP, Roelofs HM, Edler L, Kirch W, Peters WH.

World J Gastroenterol. 2013 Sep 28;19(36):6020-5. doi: 10.3748/wjg.v19.i36.6020.

21.

Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial.

Krause S, Sterzing F, Neuhof D, Edler L, Debus J, Herfarth K.

BMC Cancer. 2012 Oct 31;12:504. doi: 10.1186/1471-2407-12-504.

22.

A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma.

Roeder F, Schulz-Ertner D, Nikoghosyan AV, Huber PE, Edler L, Habl G, Krempien R, Oertel S, Saleh-Ebrahimi L, Hensley FW, Buechler MW, Debus J, Koch M, Weitz J, Bischof M.

BMC Cancer. 2012 Jul 12;12:287. doi: 10.1186/1471-2407-12-287.

23.

Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.

Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J.

Acta Oncol. 2013 Jan;52(1):147-52. doi: 10.3109/0284186X.2012.692882. Epub 2012 Jun 11.

PMID:
22686472
24.

A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.

Campa D, Müller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A.

Int J Cancer. 2012 Dec 15;131(12):2920-8. doi: 10.1002/ijc.27567. Epub 2012 Jul 3.

25.

Recent advances in the risk assessment of melamine and cyanuric acid in animal feed.

Dorne JL, Doerge DR, Vandenbroeck M, Fink-Gremmels J, Mennes W, Knutsen HK, Vernazza F, Castle L, Edler L, Benford D.

Toxicol Appl Pharmacol. 2013 Aug 1;270(3):218-29. doi: 10.1016/j.taap.2012.01.012. Epub 2012 Jan 25. Review.

PMID:
22306862
26.

An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.

Wunder C, Kopp-Schneider A, Edler L.

J Biopharm Stat. 2012;22(2):294-311. doi: 10.1080/10543406.2010.531831.

PMID:
22251175
27.

Two new approaches to improve the analysis of BALB/c 3T3 cell transformation assay data.

Hoffmann S, Hothorn LA, Edler L, Kleensang A, Suzuki M, Phrakonkham P, Gerhard D.

Mutat Res. 2012 Apr 11;744(1):36-41. doi: 10.1016/j.mrgentox.2011.12.002. Epub 2011 Dec 10.

PMID:
22178130
28.

A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer.

Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Büchler MW, Beckhove P, Huber PE, Weitz J.

BMC Cancer. 2011 Sep 30;11:419. doi: 10.1186/1471-2407-11-419.

29.

Considerations on what constitutes a 'qualified statistician' in regulatory guidelines.

Gerlinger C, Edler L, Friede T, Kieser M, Nakas CT, Schumacher M, Seldrup J, Victor N.

Stat Med. 2012 May 20;31(11-12):1303-5. doi: 10.1002/sim.4345. Epub 2011 Sep 21.

PMID:
21948351
30.

Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial.

Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, Jäkel O, Haberer T, Debus J.

BMC Cancer. 2011 Feb 12;11:67. doi: 10.1186/1471-2407-11-67.

31.

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21.

PMID:
21170759
32.

Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer.

Knoefel LF, Werle-Schneider G, Dally H, Müller PJ, Edler L, Bartsch H, Tuengerthal S, Heussel CP, Reinmuth N, Thomas M, Risch A.

J Thorac Oncol. 2011 Jan;6(1):183-9. doi: 10.1097/JTO.0b013e3181f8a20e.

33.

Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.

Combs SE, Edler L, Burkholder I, Rieken S, Habermehl D, Jäkel O, Haberer T, Unterberg A, Wick W, Debus J, Haselmann R.

BMC Cancer. 2010 Nov 9;10:615. doi: 10.1186/1471-2407-10-615.

34.

Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.

Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J.

BMC Cancer. 2010 Oct 6;10:533. doi: 10.1186/1471-2407-10-533.

35.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, Schadendorf D.

Br J Cancer. 2010 Sep 7;103(6):820-6. doi: 10.1038/sj.bjc.6605796. Epub 2010 Aug 24.

36.

Anti-annexin 1 antibodies: a new diagnostic marker in the serum of patients with discoid lupus erythematosus.

Kretz CC, Norpo M, Abeler-Dörner L, Linke B, Haust M, Edler L, Krammer PH, Kuhn A.

Exp Dermatol. 2010 Oct;19(10):919-21. doi: 10.1111/j.1600-0625.2010.01145.x.

PMID:
20701627
37.

Temporal lobe reactions after radiotherapy with carbon ions: incidence and estimation of the relative biological effectiveness by the local effect model.

Schlampp I, Karger CP, Jäkel O, Scholz M, Didinger B, Nikoghosyan A, Hoess A, Krämer M, Edler L, Debus J, Schulz-Ertner D.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):815-23. doi: 10.1016/j.ijrobp.2010.03.001. Epub 2010 Jul 16.

PMID:
20638186
38.

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.

Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E.

Cancer. 2010 Sep 1;116(17):4114-21. doi: 10.1002/cncr.25196.

39.

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5. No abstract available.

PMID:
20557849
40.

10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.

Edler L, Sehrt D, Scheulen ME.

Int J Clin Pharmacol Ther. 2010 Jul;48(7):435-9. No abstract available.

41.

IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes.

DeCarlo CA, Severini A, Edler L, Escott NG, Lambert PF, Ulanova M, Zehbe I.

Lab Invest. 2010 Oct;90(10):1482-91. doi: 10.1038/labinvest.2010.95. Epub 2010 May 17.

42.

CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site.

Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, Konecki K, Klussmann S, Corsini NS, Kleber S, Drost N, Neumann A, Lévi-Strauss M, Brors B, Gretz N, Edler L, Fischer C, Hill O, Thiemann M, Biglari B, Karray S, Martin-Villalba A.

Immunity. 2010 Feb 26;32(2):240-52. doi: 10.1016/j.immuni.2010.01.011. Epub 2010 Feb 11.

43.

Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.

Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Münch M, Müller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevogt P, Fogel M.

J Pathol. 2010 Apr;220(5):551-61. doi: 10.1002/path.2673.

PMID:
20077528
44.

4.4 The proposed replacement of the no observed adverse effect level with benchmark dose levels in food risk assessment.

Edler L.

Hum Exp Toxicol. 2009 Feb;28(2-3):135. doi: 10.1177/0960327109105771. No abstract available.

PMID:
19713379
45.

3.2 Quantification of uncertainty within and between species and the role of uncertainty factors.

Edler L.

Hum Exp Toxicol. 2009 Feb;28(2-3):115-7. doi: 10.1177/0960327109105765. No abstract available.

PMID:
19713374
46.

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis.

Scherf DB, Dally H, Müller P, Werle-Schneider G, Jäger B, Edler L, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A.

Eur Respir J. 2010 Feb;35(2):381-90. doi: 10.1183/09031936.00125608. Epub 2009 Jul 30.

47.

Long-term outcome and survival of surgically treated supratentorial low-grade glioma in adult patients.

Ahmadi R, Dictus C, Hartmann C, Zürn O, Edler L, Hartmann M, Combs S, Herold-Mende C, Wirtz CR, Unterberg A.

Acta Neurochir (Wien). 2009 Nov;151(11):1359-65. doi: 10.1007/s00701-009-0435-x. Epub 2009 Jul 3. Erratum in: Acta Neurochir (Wien). 2009 Nov;151(11):1367. Rezvan, Ahmadi [corrected to Ahmadi, Rezvan]; Christine, Dictus [corrected to Dictus, Christine]; Christian, Hartmann [corrected to Hartmann, Christian]; Olga, Zürn [corrected to Zürn, Olga]; Lutz, Edler [corrected to Edler, Lutz]; Marius, Hartmann [corr.

PMID:
19575144
48.

"ToxRTool", a new tool to assess the reliability of toxicological data.

Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-Ovaskainen A, Hartung T, Hoffmann S.

Toxicol Lett. 2009 Sep 10;189(2):138-44. doi: 10.1016/j.toxlet.2009.05.013. Epub 2009 May 27.

PMID:
19477248
49.

Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.

Zubel A, Flechtenmacher C, Edler L, Alonso A.

Gynecol Oncol. 2009 Aug;114(2):332-6. doi: 10.1016/j.ygyno.2009.05.005. Epub 2009 May 27.

PMID:
19473694
50.

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms.

Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Tołoczko-Grabarek A, Gilbert M, Edler L, Zapatka M, Eils R, Lubiński J, Scott RJ, Hamann U.

Breast Cancer Res Treat. 2010 Jan;119(1):201-11. doi: 10.1007/s10549-009-0390-5. Epub 2009 Apr 10.

PMID:
19360465

Supplemental Content

Support Center